The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet and triplet regimens but also as quadruplets is driving the sales of multiple myeloma drugs. While Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of therapy for multiple myeloma, emerging agents such as Sanofi / ImmunoGen’s isatuximab, Oncopeptides’ Ygalo, Karyopharm Therapeutics’ Xpovio / selinexor, BMS / Bluebird Bio’s idecabtagene vicleucel / bb2121, and GlaxoSmithKline’s belantamab mafodotin / GSK2857916 are pursuing initial approvals. There is immense clinical and commercial potential to be exploited in multiple myeloma for therapies that have improved efficacy, novel mechanisms of action, and cater to underserved patient segments.
How has the approval of Janssen’s Darzalex and Bristol-Myers Squibb / AbbVie’s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?
Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?
What are thought leaders’ opinions on agents in Phase III development, such as Sanofi / ImmunoGen’s isatuximab, BMS / Bluebird Bio’s idecabtagene vicleucel / bb2121, GlaxoSmithKline’s belantamab mafodotin / GSK2857916, and Janssen’s subcutaneous formulation of Darzalex?
What impact will these agents have on the multiple myeloma market? What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.